Barinthus Biotherapeutics plc (BRNS) — Cash Flow Quality Index
Barinthus Biotherapeutics plc (BRNS) has a Cash Flow Quality Index of 1.45x as of September 2022. Operating cash flow of $11.88 Million exceeds net income of $8.22 Million, indicating high earnings quality where cash backs reported profits. Explore how efficiently does Barinthus Biotherapeutics plc generate cash to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Barinthus Biotherapeutics plc Cash Flow Quality Index (2022–2022)
Historical Cash Flow Quality Index for Barinthus Biotherapeutics plc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Barinthus Biotherapeutics plc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Barinthus Biotherapeutics plc (2022–2022)
Year-by-year earnings quality comparison for Barinthus Biotherapeutics plc. For live market cap and the full company financial profile, see Barinthus Biotherapeutics plc (BRNS) market capitalisation.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2022 | -2.71x | $-14.43 Million | $5.32 Million | — |